Item 7.01. Regulation FD Disclosure.
On
Pursuant to General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor is it to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless the Company expressly sets forth in such future filings that such information is to be considered "filed" or incorporated by reference therein, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in any such filing.
Item 8.01. Other Events.
As noted above, On
Item 9.01. Financial Statements and Exhibits (d) Exhibits: 99.1Windtree Therapeutics, Inc. Presentation datedDecember 11, 2019 .
Cautionary Note Regarding Forward-looking Statements:
To the extent that statements in this Current Report on Form 8-K are not
strictly historical, including statements as to business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future financial
conditions, future collaboration agreements, the success of the Company's
product development, cash flows, future revenues, the timing of planned clinical
trials or otherwise as to future events, such statements are forward-looking,
and are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements contained in this
Current Report are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made. Such risks and
others are further described in the Company's filings with the
--------------------------------------------------------------------------------
© Edgar Online, source